AR and prostate cancer: These findings suggest some advantage of immunotherapy in old-PD patients and BET bromodomain inhibitors in young-PD, which block prostate cancer cell growth through c-MYC and androgen receptor (AR) suppression can be used in the prostate cancer subset of patients based on the age and tumor type.